Day: March 15, 2022

Wee-Cig, EZ365 CEO Russell Korus to Share Industry Leading Expertise on NFTs at the 2022 Artificial Intelligence and Blockchain UAE Expo in Dubai

Written by Customer Service on March 15, 2022. Posted in Public Companies.

Korus will educate participating investors and enhance public understanding of NFTs and their incredible potential Las Vegas, NV, March 15, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Wee-Cig International Corporation (OTCMarkets: WCIG), a company focused on identifying and growing top tech companies in emerging markets, today announced that CEO and Founder of operating subsidiary dba, “EZ365”, Russell Korus, will be a featured speaker at the upcoming Artificial Intelligence and Blockchain (AIBC) 2022 UAE Expo in Dubai March 20 through 23. In his dynamic presentation “NFTs: What Are They and Why Should You Care?” Korus will educate and inspire new entrants to the world of blockchain-based digital assets, especially those considering investing in NFTs. “Anyone looking to participate in the excitement and opportunity of the...

Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer

Written by Customer Service on March 15, 2022. Posted in Public Companies.

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present an analysis based on the June 10th, 2021 data cut from the expansion cohort of the Company’s Phase 1 trial of upifitamab rilsodotin (UpRi) at the upcoming Society of Gynecologic Oncology Annual Meeting on Women’s Cancer being held from March 18-21, 2022 in Phoenix, Arizona. UpRi is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combinations starting...

Reservoir Announces Publishing Deal With Grammy-Winning Artist and Songwriter Killer Mike

Written by Customer Service on March 15, 2022. Posted in Public Companies.

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) — Reservoir Media, Inc. (NASDAQ: RSVR) (“Reservoir” or the “Company”), an award-winning independent music company, today announced a global publishing deal with Grammy-winning artist and songwriter Michael Render aka Killer Mike, who is part of the popular hip-hop super duo, Run The Jewels. The deal includes his entire catalog and future works. The Atlanta-born Mike has released four studio albums alongside his Run The Jewels partner, EL-P. Their most recent, RTJ4, soared to the Top 10 on the Billboard 200 and was met with widespread critical acclaim, landing at #1 on NME’s The Best 50 Albums of 2020 list. Named the 2020 Spin Magazine Artist of the Year, Run The Jewels have won eleven Libera Awards, including the 2021 A2IM Humanitarian Award, took home four Clio Awards, including two Gold-winning...

MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference

Written by Customer Service on March 15, 2022. Posted in Public Companies.

MARIETTA, Ga., March 15, 2022 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the Canaccord Genuity Musculoskeletal Conference in Chicago on Tuesday, March 22 at 10:30 AM CDT / 11:30 AM EDT. Institutional investors interested in a meeting with management during the conference may reach out to their Canaccord Genuity representative. Investors and other interested parties may access the live webcast on the Events page of the Investors section of the Company’s website or by clicking here. A replay of the webcast will be available for 30 days on the Company’s website at www.mimedx.com. About MIMEDXMIMEDX is a transformational...

Enphase Energy Acquires SolarLeadFactory

Written by Customer Service on March 15, 2022. Posted in Mergers And Acquisitions.

Provides Installers with High Quality Leads That Lower Customer Acquisition Costs FREMONT, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, announced today the acquisition of SolarLeadFactory LLC. Founded in 2012, the company provides high quality leads to solar installers. SolarLeadFactory has joined Enphase with the objective of substantially increasing lead volumes and conversion rates to help drive down the customer acquisition costs for installers. Enphase has set out to build a digital platform for installers that incorporates tools to design, permit, install, monitor, and maintain solar and battery systems. This acquisition adds lead generation capabilities to that toolset....

OptimizeRx Acquires EvinceMed, a Specialty Drug Prescription Initiation Platform

Written by Customer Service on March 15, 2022. Posted in Mergers And Acquisitions.

OptimizeRx expands reach of its point-of-care solutions to simplify the prescribing process of specialty medications for healthcare providers, and to enable greater access for patients ROCHESTER, Mich., March 15, 2022 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced a definitive agreement to acquire the EvinceMed platform and related assets. EvinceMed is a leader in delivering end-to-end automation for specialty pharmaceutical transactions. The acquisition includes the full Market Access Management Platform supporting pharma manufacturers, hub providers and pharmacies to improve patient access, speed to therapy and activation of affordability programs. With the EvinceMed platform, OptimizeRx will...

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

Written by Customer Service on March 15, 2022. Posted in Earnings Releases And Operating Results.

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2021. “In 2021, we sharpened the focus of our pipeline strategy and further underscored the therapeutic value of our lead candidate, UBX1325, a novel senolytic small molecule with disease-modifying potential, for the treatment of diabetic macular edema (DME) and age-related macular degeneration (AMD),” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “Supported by strong underlying biology as evidenced by preclinical data, and impressive results from our Phase 1 study in patients with DME or AMD, we believe UBX1325 has the...

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 15, 2022. Posted in Earnings Releases And Operating Results.

Ovid executing on its strategy to build a leading epilepsy pipelineOV329 expected to enter the clinic in 2022Organization reshaped to reduce personnel by 20% and increase operational efficiencyTargeted business development continues to support the pipelineNEW YORK, March 15, 2022 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. “Ovid is disciplined in our focus to become a leader in epilepsy therapies. We are advancing a pipeline with novel mechanisms of action, which we hope will become medicines for the nearly 20-40% of epilepsy patients...

ERES REIT Declares March 2022 Monthly Distribution

Written by Customer Service on March 15, 2022. Posted in Dividend Reports And Estimates.

TORONTO, March 15, 2022 (GLOBE NEWSWIRE) — European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) is pleased to announce that the trustees of ERES have declared the March 2022 monthly cash distribution of €0.01 per Unit and Class B LP Unit (the “March Distribution”), being equivalent to €0.12 per Unit annualized. The distribution will be payable to holders of the Units and Class B LP Units (the “Unitholders”) of record on March 31, 2022, with payment on April 18, 2022. The Euro-denominated distribution will be paid in Canadian dollars based on the exchange rate on the date of payment (estimated C$0.01388 per Unit and Class B LP Unit). Registered Unitholders will be provided with an option to elect to receive such distribution in Euros rather than Canadian dollars. If no such election is made, registered Unitholders...

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 15, 2022. Posted in Earnings Releases And Operating Results.

On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022 $291.1 million in cash and cash equivalents as of December 31, 2021 to advance pipeline of EEV-therapeutic candidates BOSTON, March 15, 2022 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the fourth quarter and full year ending December 31, 2021 and highlighted recent business updates. “The fourth quarter of 2021 marked a significant milestone for Entrada, as we secured approximately $209 million in gross proceeds from our initial public offering and became a Nasdaq-listed company,” said Dipal Doshi, President...

Day: March 15, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals